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 ABSTRACT 
 Objectives  The aim of this study was to confi rm the 
infl uence of  TNFSF4 polymorphisms on systemic sclerosis 
(SSc) susceptibility and phenotypic features. 
 Methods  A total of 8 European populations of 
Caucasian ancestry were included, comprising 3014 
patients with SSc and 3125 healthy controls. Four 
genetic variants of  TNFSF4 gene promoter (rs1234314, 
rs844644, rs844648 and rs12039904) were selected as 
genetic markers. 
 Results  A pooled analysis revealed the association of 
rs1234314 and rs12039904 polymorphisms with SSc (OR 
1.15, 95% CI 1.02 to 1.31; OR 1.18, 95% CI 1.08 to 1.29, 
respectively). Signifi cant association of the four tested 
variants with patients with limited cutaneous SSc (lcSSc) 
was revealed (rs1234314 OR 1.22, 95% CI 1.07 to 1.38; 
rs844644 OR 0.91, 95% CI 0.83 to 0.99; rs844648 OR 
1.10, 95% CI 1.01 to 1.20 and rs12039904 OR 1.20, 95% 
CI 1.09 to 1.33). Association of rs1234314, rs844648 and 
rs12039904 minor alleles with patients positive for anti-
centromere antibodies (ACA) remained signifi cant (OR 
1.23, 95% CI 1.10 to 1.37; OR 1.12, 95% CI 1.01 to 1.25; 
OR 1.22, 95% CI 1.07 to 1.38, respectively). Haplotype 
analysis confi rmed a protective haplotype associated with 
SSc, lcSSc and ACA positive subgroups (OR 0.88, 95% CI 
0.82 to 0.96; OR 0.88, 95% CI 0.80 to 0.96; OR 0.86, 95% 
CI 0.77 to 0.97, respectively) and revealed a new risk 
haplotype associated with the same groups of patients 
(OR 1.14, 95% CI 1.03 to 1.26; OR 1.20, 95% CI 1.08 to 
1.35; OR 1.23, 95% CI 1.07 to 1.42, respectively). 
 Conclusions  The data confi rm the infl uence of 
 TNFSF4 polymorphisms in SSc genetic susceptibility, 
especially in subsets of patients positive for lcSSc and 
ACA. 
 INTRODUCTION 
 Systemic sclerosis (SSc) is a connective tissue disor-
der characterised by ﬁ brosis, vascular damage and 
immune imbalance. This pathology has a complex 
polygenic aetiology and variable clinical manifesta-
tions. Patients with SSc are commonly classiﬁ ed in 
two major subgroups: limited cutaneous systemic 
sclerosis (lcSSc) and diffuse cutaneous systemic 
sclerosis (dcSSc).  1  Autoantibody status, especially 
anti-centromere antibodies (ACA) and anti-topoi-
somerase antibodies (ATA), is clinically used as 
prognostic biomarker.  1  
 Familial clustering and ethnic inﬂ uences sup-
port the genetic component of this disease.  2  
Initially, only major histocompatibility complex 
(MHC) genes were ﬁ rmly associated with SSc.  2  
Nevertheless, recently a number of candidate genes 
such as  STAT4 ,  BANK1 or  IRF5 , have been related 
to SSc genetic predisposition in independent popu-
lations by well powered studies.  3  Hypothesis free 
approaches such as genome-wide association stud-
ies, have lately conﬁ rmed the role of  MHC ,  IRF5 
and  STAT4 and uncovered new SSc susceptibility 
loci, such as  CD247 .  4    5  
 In this line of research, four  TNFSF4 promoter 
single nucleotide polymorphisms (SNPs) rs1234314, 
rs844644, rs844648 and rs12039904 were recently 
implicated in susceptibility to SSc in a Caucasian 
American population (composed of 1059 patients 
with SSc and 698 healthy controls).  6  Interestingly, 
the  TNFSF4 gene, which encodes OX40L, is con-
sidered as a potential autoimmunity candidate 
gene. OX40L is expressed on activated antigen 
presenting cells and endothelial cells in acute 
 A replication study confi rms the association of 
 TNFSF4 (OX40L) polymorphisms with systemic 
sclerosis in a large European cohort 
 Lara  Bossini-Castillo, 1  Jasper C A  Broen, 2  Carmen P  Simeon, 3  Lorenzo  Beretta, 4 
 Madelon C  Vonk, 2  Norberto  Ortego-Centeno, 5  Gerard  Espinosa, 6  Patricia  Carreira, 7 
 María Teresa  Camps, 8  Nuria  Navarrete, 9  María F  González-Escribano, 10  Esther  Vicente-
Rabaneda, 11  Luis  Rodríguez, 12  Carlos  Tolosa, 13  José A  Román-Ivorra, 14  Inmaculada 
 Gómez-Gracia, 15  Francisco J  García-Hernández, 16  Iván  Castellví, 17  María  Gallego, 18 
 Antonio  Fernández-Nebro, 19  Rosa  García-Portales, 20  María Victoria  Egurbide, 21  Vicente 
 Fonollosa, 3  Paloma García  de la Peña, 22  Ana  Pros, 23  Miguel A  González-Gay, 24  Roger 
 Hesselstrand, 25  Gabriela  Riemekasten, 26  Torsten  Witte, 27  Marieke J H  Coenen, 28 
 Bobby P  Koeleman, 29  Frederic  Houssiau, 30  Vanessa  Smith, 31  Filip de  Keyser, 31  Rene 
 Westhovens, 32  Ellen De  Langhe, 32  Alexandre E  Voskuyl, 33  Annemie J  Schuerwegh, 34 
 Meng May  Chee, 35  Rajan  Madhok, 35  Paul  Shiels, 35  Carmen  Fonseca, 36  Christopher 
 Denton, 36  Kathleen  Claes, 37  Leonid  Padykov, 38  Annika  Nordin, 38  Øyvind  Palm, 39 
 Benedicte A  Lie, 40  Paolo  Airó, 41  Raffaella  Scorza, 4  Jacob M  van Laar, 42  Nicolas 
 Hunzelmann, 43  Alexander  Kreuter, 44  Ariane  Herrick, 45  Jane  Worthington, 45  Timothy R D 
J  Radstake, 2  Javier  Martín, 1  Blanca  Rueda 1,10 
14_annrheumdis141838.indd   638 2/28/2011   1:04:37 PM
Concise report
Ann Rheum Dis 2011;70:638–641. doi:10.1136/ard.2010.141838 639
 RESULTS 
 Analysis of TNFSF4 promoter polymorphisms 
 The allelic frequencies of the four SNPs tested were similar to 
those reported for Caucasian populations in previous studies  6    12    13  
and the international HapMap Project ( http://hapmap.ncbi.nlm.
nih.gov/ ). In addition, the genotypic distribution of healthy con-
trols and SSc cases was in HWE for all SNPs. 
 Table 1 describes allelic distribution of the four SNPs in the 
pooled analysis, and supplementary tables 1–4 contain detailed 
data for each population. Pooled analysis of rs1234314 SNP 
showed statistically signiﬁ cant association of the G allele with 
SSc (p=0.03, OR 1.15, 95% CI 1.02 to 1.31), with the subset of 
patients with lcSSc (p=0.003, OR 1.22, 95% CI 1.07 to 1.38) and 
with patients positive for ACA (p=2.51E-04, OR 1.23, 95% CI 
1.10 to 1.37) (table 1 and supplementary ﬁ gure 1). The associa-
tion of this genetic marker with lcSSc remained signiﬁ cant after 
the comparison of this subgroup of patients with those having 
dcSSc (p=0.01, OR 0.85, 95% CI 0.75 to 0.96, data not shown). 
Pooled analysis revealed a signiﬁ cant protective association of 
rs844644 minor allele with lcSSc (p=0.03, OR 0.91, 95% CI 0.83 
to 0.99) ( table 1 , supplementary ﬁ gure 2). Similarly, the rs844648 
A allele showed a signiﬁ cant association with susceptibility to 
lcSSc and ACA positive subgroups (p=0.04, OR 1.10, 95% CI 
1.01 to 1.20; p=0.04, OR 1.12, 95% CI 1.01 to 1.25, respectively) 
( table 1 , supplementary ﬁ gure 3). Pooled analysis revealed a 
strong association of rs12039904 T allele with patients with SSc 
(p=1.53E-04, OR 1.18, 95% CI 1.08 to 1.29), with patients in the 
lcSSc subgroup (p=2.81E-04, OR 1.20, 95% CI 1.09 to 1.33) and 
patients in the ACA-positive subgroup (p=2.09E-03, OR 1.22, 
95% CI 1.07 to 1.38) ( table 1 , supplementary ﬁ gure 4). 
 TNFSF4 haplotype analysis 
 Haplotypes represented in over 5% of the healthy controls 
in any of the eight populations considered, were selected for 
pooled analysis ( table 2 and supplementary table 5). Linkage 
disequilibrium patterns were tested in each of the eight cohorts 
analysed (supplementary table 6). Only two haplotypes reached 
signiﬁ cant association with SSc, CAGC (p=2.30E-03, OR 0.88, 
95% CI 0.82 to 0.96) and GCAT (p=9.10E-03, OR 1.14, 95% 
CI 1.03 to 1.26) (supplementary table 5) (the order of the SNPs 
is rs1234314-rs844644-rs844648-rs12039904). Interestingly, the 
CAGC haplotype is composed by the protective alleles of all 
the tested SNPs while the GCAT haplotype harbours all the 
risk alleles. The association of CAGC and GCAT haplotypes 
with SSc clinical features remained signiﬁ cant for patients in the 
lcSSc (p=6.8E-03, OR 0.88, 95% CI 0.80 to 0.96; p=1.3E-03, OR 
1.20, 95% CI 1.08 to 1.35, respectively, data not shown) and 
ACA-positive subsets (p=0.01, OR 0.86, 95% CI 0.77 to 0.97; 
p=3.7E-03, OR 1.23, 95% CI 1.07 to 1.42, respectively, data not 
shown). 
 DISCUSSION 
 TNFSF4 polymorphisms have been related to susceptibility for 
different autoimmune diseases including SSc.  6    14  With the aim 
of validating the initially reported association of  TNFSF4 gene in 
SSc, we conducted a large case-control study and a pooled anal-
ysis in eight independent European populations of Caucasian 
ancestry. 
 In accordance with the report by Gourh  et al,  6  our study sup-
ports the implication of  TNFSF4 gene promoter polymorphisms 
in SSc genetic predisposition. Stratiﬁ cation by SSc clinical sub-
type or autoantibody status conﬁ rmed the signiﬁ cant association 
of the  TNFSF4 variants with the patients in the lcSSc subset and 
inﬂ ammation. Furthermore, it enhances B cell proliferation and 
differentiation,  7  and its binding to OX40 (CD134) promotes pro-
liferation and survival of T cells.  8  All these processes could play 
an important role in loss of immune tolerance and pathology as 
observed in SSc. 
 On this basis, the aim of this study was to replicate the asso-
ciation of  TNFSF4 gene promoter polymorphisms with SSc 
through a large association study in eight independent European 
populations of Caucasian ancestry, in order to conﬁ rm the impli-
cation of  TNFSF4 gene in SSc genetic susceptibility and pheno-
typic features. 
 PATIENTS AND METHODS 
 Patients 
 A total of 3014 cases and 3125 controls from 8 European 
Caucasian cohorts (Spain, Germany, The Netherlands, Belgium, 
Italy, Sweden, Norway and UK) were included in this study. 
Patients with SSc were diagnosed accordingly with the 1980 
American College of Rheumatology classiﬁ cation criteria for 
SSc,  9  and were subdivided into those with lcSSc and dcSSc as 
deﬁ ned by LeRoy  et al .  10  
 The following clinical data was collected for ascertainment 
of clinical phenotype of patients with SSc: age, gender, disease 
duration and presence of SSc speciﬁ c autoantibodies, ATA and 
ACA. Clinical subtype information was available for 82% of 
the patients, and autoantibody status was available for 74% 
of the patients. The control population consisted of unrelated 
healthy individuals recruited in the same geographical regions 
as patients with SSc, matched by age, sex and ethnicity. The 
local ethical committees at all participating centres approved 
the study. Patients and controls were included in the study after 
written informed consent was obtained. 
 TNFSF4 polymorphisms genotyping 
 SNPs rs1234314, rs844644, rs844648 and rs12039904 (tag-SNP 
of rs2205960 SNP) were genotyped using TaqMan SNP genotyp-
ing assays in a 7900HT Real-Time PCR System from Applied 
Biosystems (Foster City, California, USA).  The genotyping call 
rate was over 93% in all cases and controls included. 
 Statistical analysis 
 Association was calculated by 2×2 contingency tables and 
Fisher’s exact test or χ  2  when necessary, obtaining p values, 
OR and 95% CI using PLINK (V.1.06;  http://pngu.mgh.har-
vard.edu/purcell/plink/ ). p Values below 0.05 after Benjamini 
and Hochberg False Discovery Rate Method correction 
were considered as statistically signiﬁ cant. Hardy–Weinberg 
equilibrium (HWE) was tested for all SNPs at signiﬁ cance 
level=0.01. 
 Haplotypes were constructed using PLINK (V.1.06) and 
Haploview V.4.2 ( http://www.broadinstitute.org/haploview/
haploview ). Haplotypes having a frequency <5% in control 
groups were excluded for the analysis. Haplotype p values were 
corrected using Bonferroni correction. Meta-analysis was car-
ried out by PLINK (V.1.06) and StatsDirect (V.2.6.6; StatsDirect, 
Altrincham, UK) in the case of haplotypes. Homogeneity 
among cohorts was calculated using the Breslow–Day method, 
and OR calculation was performed under ﬁ xed effects model 
(Mantel–Haenszel) or random effects (DerSimonian–Laird) 
when necessary. 
 The power of the study for the whole set of patients and con-
trols reached over 98% (Power Calculator for Genetic Studies 
2006  11  ). 
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haplotypes to the ones reported in this study. Moreover, func-
tional data showed that the risk haplotype produced an increased 
level of  TNFSF4 transcript (compared to the protective haplo-
type), and a higher surface expression of OX40L in lymphoblas-
toid cell lines and peripheral blood lymphocytes after activation. 
This overexpression seems to be related to the destruction of 
the DNA binding site for the transcriptional repressor E4BP4 
(with a role in the survival of early B cell progenitors).  12  Thus, 
the  TNFSF4 risk haplotype associated with SSc and producing 
higher levels of OX40L might be implicated in the pathogenic 
mechanisms of SSc, by the alteration of regulatory processes 
controlling B and T cell proliferation and differentiation, leading 
to autoantibody production and tissue damage.  7    8    14  –  16  Further 
ACA-positive subgroup but not with patients in the dcSSc or 
ATA-positive subsets. Nevertheless, the risk or protective direc-
tions in the associations were consistent with those reported by 
Gourh  et al.  6  
 Similarly, haplotype pooled analysis results obtained in the 
present study keep in with the ﬁ ndings from Gourh  et al.  6  
The most represented haplotype in both reports are equiva-
lent, appear in similar frequency and have a protective effect. 
Nevertheless, in our study the opposite haplotype GCAT, which 
could not be observed in the previous study, showed a signiﬁ -
cant risk association with SSc. 
 Interestingly, previous ﬁ ndings in systemic lupus erythema-
tosus revealed the existence of equivalent protective and risk 
 Table 1  Pooled analysis of  TNFSF4 promoter genetic variants 
 SNP (minor/major alleles), 
chromosome position (bp)   N  MAF  P  MH   P  FDR   OR (95% CI) 
rs1234314 (G/C), 171444015 Controls 2920 0.41    
SSc 2856 0.44 0.03*† – 1.15 (1.02 to 1.31)
lcSSc 1608 0.46 0.003*‡ – 1.22 (1.07 to 1.38)
dcSSc 724 0.42 0.75§ 0.84 1.02 (0.91 to 1.15)
ACA+ 828 0.46 2.51E-04¶ 0.001 1.23 (1.10 to 1.37)
ATA+ 519 0.42 0.23** 0.43 1.08 (0.95 to 1.24)
rs844644 (A/C), 171476118 Controls 2946 0.47    
SSc 2912 0.45 0.049† 0.07 0.93 (0.86 to 1.00)
lcSSc 1653 0.45 0.03‡ 0.04 0.91 (0.83 to 0.99)
dcSSc 743 0.46 0.84§ 0.84 0.99 (0.88 to 1.11)
ACA+ 856 0.44 0.049¶ 0.049 0.90 (0.80 to 1.00)
ATA+ 533 0.46 0.33** 0.43 0.94 (0.82 to 1.07)
rs844648 (A/G), 171490486 Controls 2977 0.43    
SSc 2940 0.44 0.07† 0.07 1.07 (1.00 to 1.15)
lcSSc 1673 0.45 0.04‡ 0.04 1.1 (1.01 to 1.20)
dcSSc 742 0.42 0.69§ 0.84 0.98 (0.87 to 1.10)
ACA+ 860 0.45 0.04¶ 0.049 1.12 (1.01 to 1.25)
ATA+ 529 0.42 0.74** 0.74 1.02 (0.89 to 1.17)
rs12039904 (T/C), 171478896 Controls 2991 0.23    
SSc 2894 0.26 1.53E-04† 6.12E-04 1.18 (1.08 to 1.29)
lcSSc 1639 0.26 2.81E-04‡ 5.61E-04 1.20 (1.09 to 1.33)
dcSSc 735 0.24 0.3§ 0.84 1.07 (0.94 to 1.23)
ACA+ 840 0.26 2.09E-03¶ 4.17E-03 1.22 (1.07 to 1.38)
ATA+ 523 0.24 0.15** 0.43 1.12 (0.96 to 1.31)
 Controls are used as reference for all comparisons. 
 *DerSimonian–Laird random effects model p value. 
 †Breslow–Day rs1234314 p=0.01; rs844644 p=0.23; rs844648 p=0.52; rs12039904 p=0.50. 
 ‡Breslow–Day rs1234314 p=0.08; rs844644 p=0.52; rs844648 p=0.33; rs12039904 p=0.48. 
 §Breslow–Day rs1234314 p=0.61; rs844644 p=0.49; rs844648 p=1.00; rs12039904 p=0.38. 
 ¶Breslow–Day rs1234314 p=0.29; rs844644 p=0.79; rs844648 p=0.94; rs12039904 p=0.74. 
 **Breslow–Day rs1234314 p=0.41; rs844644 p=0.73; rs844648 p=0.71; rs12039904 p=0.56. 
 ACA, anti-centromere antibodies; ATA, anti-topoisomerase antibodies; chromosome position, position in chromosome 1; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited 
cutaneous systemic sclerosis; MAF, minor allele frequency; P FDR , corrected p value using Benjamini and Hochberg False Discovery Rate; P MH , allelic Mantel–Haenszel fi xed effects 
model p value; SSc, systemic sclerosis. 
 Table 2  Pooled analysis of  TNFSF4 haplotypes in patients with systemic sclerosis and controls 
 (2n cases/2n controls) Haplotype  Cases (%)  Controls (%)  P  MH   OR (95% CI) 
Pooled (5222/5296) CAGC 40.49 43.19 2.30E-03* 0.88 (0.82 to 0.96)
CCGC 10.23 10.04 0.47†‡ 1.09 (0.86 to 1.39)
GAGC 4.43 3.75 0.08§ 1.20 (0.98 to 1.47)
GCAC 16.71 16.68 0.53¶ 0.97 (0.87 to 1.07)
GCAT 21.54 19.33 9.10E-03** 1.14 (1.03 to 1.26)
 Others 6.60 7.01 0.67*†† 0.94 (0.73 to 1.23)
The order of the SNPs is rs1234314-rs844644-rs844648-rs12039904.
*Breslow–Day p=0.22.
†DerSimonian–Laird random effects model p value.
‡Breslow–Day p=0.004. 
§Breslow–Day p=0.62.
¶Breslow–Day p=0.16.
**Breslow–Day p=0.24.
††Breslow–Day p=0.01.
PMH, allelic Mantel–Haenszel fi xed effects model p value.
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studies are necessary to elucidate the exact molecular mecha-
nisms by which OX40L is implicated in SSc pathogenesis and 
more precisely how it can lead to the development of lcSSc and 
ACA production. 
 In summary, our results conﬁ rm the implication of  TNFSF4 
promoter polymorphisms in SSc susceptibility, especially in 
patients in the lcSSc and ACA-positive subgroups. These ﬁ nd-
ings together with previous genetic and functional studies sug-
gest  TNFSF4 as an interesting and consistent genetic factor for 
SSc and other autoimmune diseases and may open new oppor-
tunities for SSc treatment. 
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